Placenta-derived mesenchymal stem cells attenuate secondary brain injury after controlled cortical impact in rats by inhibiting matrix metalloproteinases

Background:As a form of biological therapy,placenta-derived mesenchymal stem cells(PDMSCs)exhibit considerable promise in addressing the complex pathological processes of traumaticbrain injury(TBI)due to their multi-target and multi-pathway mode of action.Material&Methods:This study investigates the protective mechanisms and benefits of PDMSCs in mitigating the effects of controlled cortical impact(CCI)in rats and glutamate-induced oxidative stress injury in HT22 cells in vitro.Our primary objective is to provide evidence supporting the clinical application of PDMSCs.Results:In the in vivo arm of our investigation,we observed a swift elevation of matrix metalloproteinase-9(MMP-9)in the proximal cortex of injured brain tissues after CCI.PDMSCs,distinguished by their heightened expression of metalloproteinase tissue inhibitors-1 and-2(TIMP-1 and TIMP-2):were intravenously administered via the caudal vein.This intervention yielded significant reductions in the permeability of the blood-brain barrier(BBB):the extent of brain edema,the levels of inflammatory cytokines IL-1βand TNF-αin damaged brain tissue,and the activation status of microglia in CCI-afflicted rats.In the realm of in vitro experiments,PDMSC-conditioned media demonstrated substantial reductions in mortality rates and cleaved caspase-3 levels in glutamate-induced HT22 cells compared with conventional media.Notably,this advantage was negated upon the introduction of neutralizing antibodies targeting TIMP-1 and TIMP-2.Conclusion:Collectively,our findings underscore the potential of PDMSCs in alleviating oxidative stress injury and secondary brain injury in the pathological process of TBI.

Association between Gene Polymorphisms and SNP-SNP Interactions of the Matrix Metalloproteinase 2 Signaling Pathway and the Risk of Vascular Senescence

Objective This study aimed to explore the association of single nucleotide polymorphisms(SNP)in the matrix metalloproteinase 2(MMP-2)signaling pathway and the risk of vascular senescence(VS).Methods In this cross-sectional study,between May and November 2022,peripheral venous blood of151 VS patients(case group)and 233 volunteers(control group)were collected.Fourteen SNPs were identified in five genes encoding the components of the MMP-2 signaling pathway,assessed through carotid-femoral pulse wave velocity(cf PWV),and analyzed using multivariate logistic regression.The multigene influence on the risk of VS was assessed using multifactor dimensionality reduction(MDR)and generalized multifactor dimensionality regression(GMDR)modeling.Results Within the multivariate logistic regression models,four SNPs were screened to have significant associations with VS:chemokine(C-C motif)ligand 2(CCL2)rs4586,MMP2 rs14070,MMP2rs7201,and MMP2 rs1053605.Carriers of the T/C genotype of MMP2 rs14070 had a 2.17-fold increased risk of developing VS compared with those of the C/C genotype,and those of the T/T genotype had a19.375-fold increased risk.CCL2 rs4586 and MMP-2 rs14070 exhibited the most significant interactions.Conclusion CCL2 rs4586,MMP-2 rs14070,MMP-2 rs7201,and MMP-2 rs1053605 polymorphisms were significantly associated with the risk of VS.

Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer

BACKGROUND A noninvasive biomarker with high diagnostic performance is urgently needed for the early diagnosis of colorectal cancer(CRC).AIM To evaluate the diagnostic value of matrix metalloproteinases(MMPs)2,7 and 9 in urine for CRC.METHODS Of 59 healthy controls,47 patients with colon polyps and 82 patients with CRC were included in this study.Carcinoembryonic antigen(CEA)in serum and MMP2,MMP7,and MMP9 in urine were detected.The combined diagnostic model of the indicators was established by binary logistic regression.The receiver operating characteristic curve(ROC)of the subjects was used to evaluate the independent and combined diagnostic value of the indicators.RESULTS The MMP2,MMP7,MMP9,and CEA levels in the CRC group differed significantly from levels in the healthy controls(P<0.05).The levels of MMP7,MMP9,and CEA also differed significantly between the CRC group and the colon polyps group(P<0.05).The area under the curve(AUC)distinguishing between the healthy control and the CRC patients using the joint model with CEA,MMP2,MMP7 and MMP9 was 0.977,and the sensitivity and specificity were 95.10%and 91.50%,respectively.For early-stage CRC,the AUC was 0.975,and the sensitivity and specificity were 94.30%and 98.30%,respectively.For advanced stage CRC,the AUC was 0.979,and the sensitivity and specificity were 95.70%and 91.50%,respectively.Using CEA,MMP7 and MMP9 to jointly established a model distinguishing the colorectal polyp group from the CRC group,the AUC was 0.849,and the sensitivity and specificity were 84.10%and 70.20%,respectively.For early-stage CRC,the AUC was 0.818,and the sensitivity and specificity were 76.30%and 72.30%,respectively.For advanced stage CRC,the AUC was 0.875,and the sensitivity and specificity were 81.80%and 72.30%,respectively.CONCLUSION MMP2,MMP7 and MMP 9 may exhibit diagnostic value for the early detection of CRC and may serve as auxiliary diagnostic markers for CRC.

Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage

A novel matrix metalloproteinase (MMP) was identified from leukocytes and found to be specifically expressedby peripheral blood leukocytes among 29 different tissuesexamined. Named leukolysin, it encodes for 562 residueswith a conserved MMP structure, i.e., pre-, pro-, catalytic , hinge- and hemopexin-like domains, but also a RXK/RRmotif, known for its role in MMP zymogen activation, anda C-terminal hydrophobic segment. Overall, leukolysindisplays the strongest homology to the newly identifiedMT-MMP subgroup with 45% and 39% identities to MT4and MT1-MMPs vs 30% and 31.5% to MMP1 and 3 respectively. Unlike MT4-MMP whose proteolytic activityremains undefined, a C-terminally truncated leukolysin isexpressed as a strong gelatinolytic species at 28 kDa whichis derived from a cell-associated 34 kDa proenzyme, presumably by furin or proprotein convertase mediated removal of the propeptide (-6 kDa). By green fluorescentprotein (GFP) tagging, the intracellular proenzyme is localized to granules throughout the cell, suggesting thatactivation occur immediately prior to secretion. Taken together, leukolysin may be part of the proteolytic arsenaldeployed by leukocytes during inflammatory responses.

Correlation of extracellular matrix metalloproteinase inducer expression with inflammatory response and MMPs/TIMPs in patients with myocardial infarction

Objective:To study the correlation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression with inflammatory response and matrix metalloproteinases (MMPs) /TIMPs in patients with myocardial infarction.Methods: The patients who were diagnosed with acute myocardial infarction and the patients who were diagnosed with stable angina pectoris in the Second People's Hospital of Juancheng County between March 2014 and December 2017 were selected as the AMI group and SAP group respectively, and the healthy volunteers who received physical examination during the same period were selected as the control group. Peripheral blood was collected to detect the expression of EMMPRIN, and serum was collected to determine the contents of inflammatory cytokines and MMPs/TIMPs. Results: Peripheral blood EMMPRIN expression as well as serum ICAM1, VCAM1, IL-1β, IL-17, MMP2, MMP8 and MMP9 contents of AMI group and SAP group were significantly higher than those of control group whereas TGF-β1, sFGL-2, TIMP1 and TIMP2 contents were significantly lower than those of control group and the changes of above indexes in AMI group were more significant than those in SAP group. Serum ICAM1, VCAM1, IL-1β, IL-17, MMP2, MMP8 and MMP9 contents of AMI group of patients with high EMMPRIN expression were significantly higher than those of patients with low EMMPRIN expression whereas TGF-β1, sFGL-2, TIMP1 and TIMP2 contents were significantly lower than those of patients with low EMMPRIN expression.Conclusion:The high EMMPRIN expression in peripheral blood of patients with myocardial infarction can aggravate the inflammatory response and destroy the balance of MMPs/TIMPs.

Correlation of Claudins6 (CLDN6) gene expression in meningioma tissue with the expression of matrix metalloproteinases (MMPs)/tissue inhibitors of matrix metalloproteinase (TIMPs) and epithelial-mesenchymal transition (EMT) genes

Objective:To study the correlation of Claudins6 (CLDN6) gene expression in meningioma tissue with the expression of matrix metalloproteinases (MMPs)/tissue inhibitors of matrix metalloproteinase (TIMPs) and epithelial-mesenchymal transition (EMT) genes.Methods:Meningioma tissue samples that were surgically removed in Yibin First People's Hospital between April 2014 and May 2017 were selected, normal arachnoid tissue samples that were collected from decompressive craniectomy in Yibin First People's Hospital during the same period were selected, and the expression of CLDN6, MMPs/TIMPs and EMT genes in tissues were determined.Results: CLDN6 protein expression in meningioma tissue was significantly lower than that in normal arachnoid tissue;EMMPRIN, MMP2, MMP9, Vimentin and N-cadherin protein expression in meningioma tissue were significantly higher than those in normal arachnoid tissue while TIMP1, TIMP2, E-cadherin andα-catenin protein expression were significantly lower than those in normal arachnoid tissue;EMMPRIN, MMP2, MMP9, Vimentin and N-cadherin protein expression in meningioma tissue with higher CLDN6 expression were significantly lower than those in meningioma tissue with lower CLDN6 expression while TIMP1, TIMP2, E-cadherin andα-catenin protein expression were significantly higher than those in meningioma tissue with lower CLDN6 expression. Conclusion: Lowly expressed CLDN6 gene in meningioma tissue can increase the hydrolysis activity of MMPs, induce epithelial-mesenchymal transition and thus promote the invasive growth of meningioma.

组织中MMP-9、E-cadherin与子宫内膜样癌伴MELF浸润方式及肿瘤侵袭程度的关系

目的分析子宫内膜样癌组织中基质金属蛋白酶(matrix metalloproteinase,MMP)-9、E-钙黏蛋白(E-cadherin)与微囊性、伸长及碎片状(microcystic,elongation,and fragmentation,MELF)浸润方式及肿瘤侵袭程度之间的关系,探讨能够识别子宫内膜样癌伴MELF浸润的指标,抑制肿瘤侵袭能力。方法回顾性分析在河北北方学院附属第一医院接受手术治疗的112例子宫内膜样癌患者临床资料,全部患者均顺利完成改良根治性子宫切除术,并获得肿瘤标准,根据病理检查结果对112例患者进行分组,分为MELF组和N-MELF组。统计112例患者一般临床资料,血液检查项目包括肿瘤标志物,免疫组织化学检查项目包括组织中MMP-9、E-cadherin,根据检查结果,构建Logistic回归模型,分析组织中MMP-9、E-cadherin及相关指标与子宫内膜样癌MELF浸润方式及肿瘤侵袭程度的关系。结果研究中112例子宫内膜样癌患者,评估为MELF浸润患者21例(18.75%);MELF浸润患者病理等级低级别,国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)ⅣA期,淋巴脉管间隙浸润(lymphatic vascular space,LVSI)、组织中MMP-9阳性患者占比多于N-MELF浸润患者,E-cadherin阳性患者占比少于N-MELF浸润患者,人附睾蛋白(humanepididymisprotein 4,HE4),甲壳质酶蛋白(human cartilageglycopmtein,YKL-40)水平高于N-MELF患者,差异有统计学意义(P<0.05)。多元Logistic回归分析提示,组织中E-cadherin表达率低、MMP-9表达率高,MELF浸润与子宫内膜样癌FIGO分期进展有关(P<0.05)。结论子宫内膜样癌发生MELF浸润与组织中MMP-9、E-cadherin有关,MMP-9表达率高和E-cadherin表达率低能够通过导致MELF浸润发生,从而增强肿瘤侵袭能力。

Inhibition of Matrix Metalloproteinases Activities by Luteolin

Matrix metalloproteinases（MMPs） are a family of zinc dependent enzymes that can degrade the components of the extracellular matrix（ECM） and basement membranes. Because MMPs play roles in many important physiological and pathological processes, many MMP inhibitors（MMPls） have been developed with the aim of interfering in and treating diseases. The authors conclude via a fluorescence based assay in vitro that luteolin inhibits the enzymatic activities of MMP-2, MMP-7, MMP-9, MMP-14, and MMP-16. This compound most specifically inhibits MMP-7 of all the MMPs tested. Finally, we used molecular modeling to dock luteolin with MMPs and revealed the binding mode of the luteolin-MMP interaction. Our results suggest that luteolin may exert its therapeutic effects via MMP inhibition.

IFN-γ、MMP-9水平在肺结核中的表达及与其病情活动性的相关性

目的 分析血清干扰素-γ(IFN-γ)、基质金属蛋白酶-9(MMP-9)水平在肺结核患者中的表达及与其病情活动性的相关性。方法 选取2019年1至2022年12月新乡医学院第一附属医院收治的264例疑似肺结核患者作为研究对象,经确诊后分为结核组(n=204例)及非结核组(n=60例),根据病情活动情况将结核组分为活动性肺结核组(n=86例)及非活动性肺结核组(n=118例),另选取同期于本院进行健康体检者80名为健康组。比较结核组、非结核组、健康组与结核组中活动性肺结核组、非活动性肺结核组及活动性肺结核中轻症组、重症组间血清IFN-γ、MMP-9水平;分析IFN-γ、MMP-9单一及联合检测肺结核的诊断效能;采用多元Logistic回归分析影响活动性肺结核患者病情程度的相关性因素。结果 三组血清IFN-γ、MMP-9水平比较:结核组>非结核组>健康组,差异具有统计学意义(P<0.05);活动性肺结核患者血清IFN-γ、MMP-9水平均显著高于非活动性肺结核,差异有统计学意义(P<0.05);86例活动性肺结核患者中轻症54例,重症32例。重症患者病程比轻症患者长,吸烟比例及血清IFN-γ、MMP-9水平均显著高于轻症患者,差异有统计学意义(P<0.05);IFN-γ、MMP-9联合诊断肺结核的灵敏度、特异度、准确度分别为93.55%、61.54%、84.09%,均高于三者单独检测(P<0.05);经Logistic回归分析,吸烟、血清IFN-γ及MMP-9均为影响活动性肺结核患者病情程度的相关因素(P<0.05)。结论 肺结核患者血清IFN-γ及MMP-9水平显著升高,二者联合对肺结核具有较好的诊断效能,且为影响活动性肺结核病情严重程度的重要影响因素,对肺结核病情评估具有重要价值。

3D打印技术用于经鼻蝶窦入路垂体腺瘤切除术应用效果及对血清MMP-9和IGF-1水平的影响

目的:探究3D打印技术在经鼻蝶窦入路垂体腺瘤(PA)切除术的应用效果及对血清基质金属蛋白酶-9(MMP-9)和胰岛素样生长因子-1(IGF-1)水平的影响。方法:选取2020年5月至2022年5月秦皇岛市第一医院收治的84例PA患者,按照随机数表法将其分为观察组和对照组,每组42例。对照组行经鼻蝶窦入路垂体腺瘤切除术,观察组行经鼻蝶窦入路垂体腺瘤切除术联合应用3D打印技术,比较两组肿瘤切除效果、围术期指标、视力改善情况、MMP-9和IGF-1水平,以及鼻腔功能的鼻气道阻力(NAR)、T&T嗅觉测试评分及并发症。结果:观察组肿瘤切除效果优于对照组,差异有统计学意义(U=2.286,P<0.05);观察组手术时间、术中出血量及住院时间均少于对照组,差异有统计学意义(t=4.780、11.438、11.842,P<0.05);术后3 d、7 d时观察组血清MMP-9和IGF-1水平低于对照组,差异有统计学意义(F=7.526、4.985,P<0.05);术后1个月、3个月时观察组NAR及T&T嗅觉测试评分低于对照组,差异有统计学意义(F=6.359、8.436,P<0.05);两组视力视野改善情况及并发症发生率比较,差异无统计学意义(P>0.05)。结论:3D打印技术用于经鼻蝶窦入路垂体腺瘤切除术可提高肿瘤切除效果,优化手术操作,减少创伤,有利于减轻疼痛,改善嗅觉功能与视力视野,并能降低血清MMP-9、IGF-1水平,且安全性较高。

白内障合并2型糖尿病患者血清ES、MMP-2、MMP-9的表达及其影响因素分析

目的:探讨白内障合并2型糖尿病患者血清血管内皮抑制素(ES)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)的表达及其影响因素。方法:选取2019年1月—2023年1月在昌邑市人民医院就诊的白内障患者90例作为研究对象,将白内障合并2型糖尿病患者48例作为试验组,白内障未合并2型糖尿病患者42例作为对照组。两组均检测血清血糖、ES、MMP-2、MMP-9水平,分析白内障合并2型糖尿病患者ES、MMP-2、MMP-9高表达的影响因素,分析白内障合并2型糖尿病患者ES水平与MMP-2、MMP-9、血糖的相关性。结果:与对照组比较,试验组空腹血糖、ES、MMP-2、MMP-9水平明显更高(P<0.05)。空腹血糖浓度是白内障合并2型糖尿病患者ES、MMP-2、MMP-9高表达的影响因素(P<0.05)。白内障合并2型糖尿病患者ES水平与MMP-2、MMP-9、空腹血糖浓度呈正相关(P<0.05)。结论:白内障合并2型糖尿病患者血清ES、MMP-2、MMP-9表达水平较高,与空腹血糖浓度有关,且血清ES水平与MMP-2、MMP-9、空腹血糖浓度呈正相关。

多西他赛联合PD-1抑制剂对晚期非小细胞肺癌预后及血清MMP-9、TIMP-1水平的影响

目的探讨多西他赛联合程序性死亡受体1(PD-1)抑制剂对晚期非小细胞肺癌(NSCLC)预后及血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)水平的影响。方法将90例晚期NSCLC患者随机分为研究组和对照组,每组45例。对照组给予多西他赛和顺铂治疗,研究组在对照组治疗基础上给予PD-1治疗,3周为1个治疗周期,共治疗6个周期。比较2组治疗后客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS),观察2组治疗期间不良反应发生情况及治疗前后血清MMP-9、TIMP-1水平的变化。结果研究组治疗后DCR、PFS、OS显著高于对照组(P<0.05);治疗期间2组不良反应发生率比较差异无统计学意义(P>0.05);2组治疗后血清MMP-9、TIMP-1水平较治疗前显著降低(P<0.05),且研究组降低较对照组更为显著(P<0.05)。结论多西他赛联合PD-1抑制剂对晚期NSCLC具有较好的疗效和预后,能够降低血清MMP-9、TIMP-1水平,降低肺癌细胞侵袭转移的能力,安全性良好。

原发性肝癌患者血清CXCLs、MMPs及外周血炎性反应指标与治疗后短期预后的相关性

目的探究原发性肝癌患者血清CXC趋化因子配体(CXCLs)、基质金属蛋白酶(MMPs)及外周血炎性反应指标与治疗后短期预后的相关性。方法选取2021年9月—2023年9月首都医科大学附属北京佑安医院普外中心收治的原发性肝癌患者117例为研究对象,根据患者治疗后3个月预后情况分为短期预后不良组(n=27)和短期预后良好组(n=90)。检测患者血清CXCLs(CXCL2、CXCL8、CXCL9、CXCL13)、MMPs(MMP-2、MMP-7、MMP-9、MMP-14)水平及外周血炎性反应指标[中性粒细胞/淋巴细胞比值(NLR)、淋巴细胞/单核细胞比值(LMR)、系统免疫炎性指数(SII)];Spearman相关性分析差异性指标与原发性肝癌患者治疗后短期预后不良的相关性;多因素Logistic回归分析原发性肝癌患者治疗后短期预后不良的影响因素。结果短期预后不良组血清CXCL8、CXCL9、CXCL13水平均高于短期预后良好组(t/P=3.876/<0.001、4.779/<0.001、5.434/<0.001);短期预后不良组血清MMP-2、MMP-7、MMP-9、MMP-14水平均高于短期预后良好组(t/P=6.775/<0.001、5.376/<0.001、6.377/<0.001、6.565/<0.001);短期预后不良组SII高于短期预后良好组(t/P=5.569/<0.001);Spearman相关性分析表明,原发性肝癌患者肿瘤长径、多发肿瘤、合并肝硬化、CXCL8、CXCL9、CXCL13、MMP-2、MMP-7、MMP-9、MMP-14、SII与治疗后短期预后不良均呈正相关(r=0.286、0.209、0.200、0.415、0.417、0.420、0.459、0.383、0.493、0.442、0.440,P均<0.05);多因素Logistic回归分析结果显示,血清CXCL8、CXCL9、CXCL13、MMP-2、MMP-7、MMP-9、MMP-14水平及SII升高是原发性肝癌患者治疗后短期预后不良的独立危险因素[OR(95%CI)=1.021(1.009~1.063)、1.043(1.006~1.082)、1.087(1.011~1.170)、1.455(1.045~2.026)、1.096(1.001~1.201)、1.027(1.011~1.074)、1.128(1.083~1.295)、1.044(1.024~1.066)]。结论血清CXCLs、MMPs水平及SII高的原发性肝癌患者治疗后短期预后往往较差,密切监测血清CXCLs、MMPs水平及SII变化对于准确评估原发性肝癌患者预后具有一定临床意义。

肝细胞癌患者血清ECM1、MMP-9和VEGF水平的变化及其意义

目的 探究肝细胞癌患者血清细胞外基质蛋白-1(ECM1)、基质金属蛋白酶-9(MMP-9和血管内皮生长因子(VEGF)水平的变化及其意义。方法 对60例肝细胞癌患者进行回顾性分析,患者主要使用甲磺酸阿帕替尼进行治疗,必要时也可联合GEMOX方案肝动脉化疗栓塞术进行治疗。采用酶联免疫吸附法测定患者治疗前后的血清ECM1、VEGF、MMP-9水平。比较患者治疗前后ECM1、MMP-9和VEGF水平;比较不同临床病理特征(年龄、性别、血管侵犯、淋巴结转移、TNM分期、Edmondson分期和肿瘤直径)患者ECM1、MMP-9和VEGF水平。结果 治疗后,患者ECM1、MMP-9以及VEGF水平分别为(135.23±44.58)pg/ml、(421.25±87.56)μg/L和(657.56±54.56)pg/ml,均低于治疗前的(215.56±30.80)pg/ml、(499.56±30.56)μg/L、(798.02±50.79)pg/ml(P<0.05)。不同年龄、性别患者ECM1、MMP-9、VEGF水平比较差异无统计学意义(P>0.05);不同血管侵犯、淋巴结转移、TNM分期、Edmondson分期和肿瘤直径患者ECM1、MMP-9、VEGF水平比较差异具有统计学意义(P<0.05)。结论 ECM1、MMP-9、VEGF三者相互作用可促进肝癌细胞的转移,可根据其水平情况,了解患者肝细胞、肝功能健康状况。

血清MMP1和P53自身抗体联合检测对食管鳞状细胞癌的诊断价值

目的:探讨食管鳞状细胞癌(ESCC)患者血清基质金属蛋白酶1(MMP1)和P53自身抗体表达水平及其联合检测的诊断意义。方法:收集2013年3—9月在汕头大学医学院附属肿瘤医院住院治疗的93例ESCC患者,并以同期90例体检者为正常对照组。应用酶联免疫吸附实验(ELISA)检测两组对象血清MMP1和P53自身抗体的表达水平,采用受试者工作特征(ROC)曲线评价诊断效能。结果:血清MMP1含量和P53自身抗体滴度在ESCC组分别为(8.076±5.912)ng/mL和0.291±0.492,正常对照组分别为(4.652±3.346)ng/mL和0.055±0.037,ESCC组均较正常对照组显著升高(均为P<0.01)。ROC曲线分析显示,MMP1诊断ESCC的曲线下面积(AUC)为0.700(95%CI为0.624~0.776),当取最佳诊断截断值7.248 ng/mL时,特异度为83.3%,敏感度为52.7%。P53自身抗体诊断ESCC的AUC为0.713(95%CI为0.638~0.788),诊断截断值为0.080,特异度为83.3%,敏感度为49.5%。两者联合检测诊断ESCC的AUC为0.787(95%CI为0.720~0.854),特异度为83.3%,敏感度为66.7%,优于单独使用MMP1或P53自身抗体。在早期ESCC中,MMP1和P53自身抗体联合检测亦能获得较好的诊断效能,AUC为0.760,95%CI为0.663~0.857,特异度为83.3%,敏感度为66.7%。结论:ESCC患者血清MMP1和P53自身抗体水平均升高,二者联合检测有助于ESCC的早期诊断,可作为ESCC的诊断标志物。

卵巢癌患者癌组织MMP-10、IL-17A、HMGB1表达与病情严重程度的相关性

目的:探究卵巢癌患者癌组织基质金属蛋白酶10(MMP-10)、白细胞介素17A(IL-17A)、高迁移率族蛋白B1(HMGB1)水平与病情严重程度相关性。方法:将407例卵巢癌患者的临床资料作为观察组,以同期就诊的216例良性卵巢肿瘤患者为对照组。检测并比较两组患者血清MMP-10、IL-17A、HMGB1水平,分析不同参数下卵巢癌患者血清MMP-10、IL-17A、HMGB1水平,利用Spearman分析卵巢癌患者血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度的相关性。结果:入院时,观察组患者血清MMP-10、IL-17A、HMGB1水平均高于对照组(P<0.05)。不同FIGO分期、分化程度、淋巴结转移卵巢癌患者中血清MMP-10、IL-17A、HMGB1水平有统计学差异(P<0.05)。Spearman分析显示血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度均呈正相关关系(P<0.05)。结论:血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度呈正相关,可作为卵巢癌患者病情严重程度的诊断指标。

颅内动脉瘤术后患者血清VEGFs、MMPs表达水平特征及对预后的预测效能

目的探讨颅内动脉瘤术后患者血清血管内皮生长因子(VEGFs)、基质金属蛋白酶(MMPs)水平特征及对预后的预测效能。方法选取2021年12月—2023年12月就诊于新疆维吾尔自治区人民医院神经外科的颅内动脉瘤术后患者121例作为研究对象,根据术后1个月预后情况将患者分为预后良好组(n=92)和预后不良组(n=29)。采用化学发光免疫测定法检测2组患者血清VEGFs、MMPs表达谱水平;Spearman相关性分析血清VEGFs、MMPs水平与颅内动脉瘤术后患者预后不良的相关性;Logistic回归分析颅内动脉瘤术后患者预后不良的危险因素;绘制受试者工作特征(ROC)曲线分析血清VEGFs、MMPs水平预测颅内动脉瘤术后患者预后不良的价值。结果预后不良组患者血清VEGF-1、VEGF-2、MMP-1、MMP-2、MMP-9水平均显著高于预后良好组患者(t/P=4.455/<0.001、3.982/<0.001、4.848/<0.001、5.702/<0.001、5.144/<0.001);血清VEGF-1、VEGF-2、MMP-1、MMP-2、MMP-9水平均与颅内动脉瘤术后患者预后不良呈显著正相关(r/P=0.338/<0.001、0.361/<0.001、0.383/<0.001、0.386/<0.001、0.331/<0.001);血清VEGF-1、VEGF-2、MMP-1、MMP-2、MMP-9水平升高均是颅内动脉瘤术后患者预后不良的独立危险因素[OR(95%CI)=1.142(1.011~1.372)、1.126(1.004~1.276)、1.027(1.002~1.052)、1.029(1.006~1.052)、1.026(1.006~1.047)];血清VEGF-1、VEGF-2、MMP-1、MMP-2、MMP-9水平独立及联合预测颅内动脉瘤术后患者预后不良的AUC分别为0.729、0.744、0.759、0.761、0.724、0.890,联合预测的效能大于各指标独立预测效能(Z/P=4.344/<0.001、4.185/<0.001、4.013/<0.001、4.010/<0.001、4.350/<0.001)。结论颅内动脉瘤术后患者血清VEGFs、MMPs表达水平与预后不良具有密切相关性。基于上述指标的联合预测模型对颅内动脉瘤术后患者不良预后有较高预测价值。

类风湿关节炎患者血清SAA、CCL20、MMP-3表达水平及临床意义

目的探讨类风湿关节炎(RA)患者血清淀粉样蛋白A(SAA)、趋化因子配体20(CCL20)及基质金属蛋白酶3(MMP-3)水平变化及临床意义。方法回顾性选取2020年9月至2023年1月大同市第五人民医院收治的RA患者108例作为研究对象,依据28个关节的疾病活动度评分(DAS28)评分,将患者分为缓解期组(n=35,DSA28评分<2.6)与活动期组(n=73,DSA28评分≥2.6),并将活动期患者进一步分为轻度活动期(n=20,DSA28评分2.6~3.2)、中度活动期(n=29,DSA28评分>3.2~5.1)与重度活动期(n=24,DSA28为>5.1);另选取同期健康体检者80名作为对照组。所有受试者均检测血清SAA、CCL20、MMP-3水平。比较不同组别血清SAA、CCL20、MMP-3水平;使用Pearson相关分析血清SAA、CCL20、MMP-3水平与红细胞沉降率(ESR)、C反应蛋白(CRP)的相关性;使用受试者工作特征(ROC)曲线评价各指标对RA疾病活动度的诊断价值。结果RA组血清SAA、CCL20、MMP-3水平分别为(42.25±13.46)mg/L、(45.69±12.78)pg/mL、(85.41±25.14)ng/mL,均显著高于对照组[(7.14±2.12)mg/L、(18.12±5.47)pg/mL、(27.36±8.21)ng/mL],差异均有统计学意义(P<0.05)。RA活动期组患者血清SAA、CCL20、MMP-3水平分别为(51.78±10.71)mg/L、(53.14±10.45)pg/mL、(106.10±20.39)ng/mL,显著高于缓解期组[(22.37±7.14)mg/L、(30.15±8.24)pg/mL、(42.25±13.64)ng/mL],差异均有统计学意义(P<0.05)。重度活动度组血清SAA、CCL20、MMP-3水平均高于中度活动度组和轻度活动度组,差异均有统计学意义(P<0.05),随着疾病活动度提高,血清SAA、CCL20、MMP-3水平逐渐增高。Pearson相关分析显示,活动期RA患者血清SAA、CCL20、MMP-3水平与CRP、ESR均呈正相关(P<0.05)。ROC曲线分析得出,血清SAA、CCL20、MMP-3区分RA轻度活动度与中度活动度的曲线下面积(AUC)分别为0.852、0.756、0.725,区分中度活动度与重度活动度的AUC分别为0.852、0.756、0.725,均显示出一定的诊断能力。结论RA患者血清SAA、CCL20、MMP-3水平均呈高表达,这3项指标可作为评估疾病活动度的生物标志物,可为临床预测病情进展提供参考。

信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌患者效果及其血清VEGF、MMP-9水平变化

目的 探讨信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌患者效果及其血清血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平变化。方法 选取2021年1月至2022年12月在周口市中心医院确诊的80例不可切除肝细胞肝癌患者,根据患者治疗方式将患者分为单抗联合组和对照组。对照组患者接受口服甲苯磺酸索拉非尼治疗,纳入36例;单抗联合组接受信迪利单抗联合贝伐珠单抗治疗,纳入44例。记录两组患者治疗4个周期后的病情控制率和客观缓解率,比较治疗前、治疗2个周期后、治疗4个周期后血清VEGF和MMP-9水平变化,比较治疗毒副作用发生情况。随访6~30个月,绘制生存曲线,比较两组患者中位总生存时间(OS)和中位无进展生存时间(PFS)。结果 单抗联合组患者病情控制率和客观缓解率分别为77.27%和25.00%,对照组分别为44.44%和5.56%,差异有统计学意义(P<0.05)。治疗后,单抗联合组患者血清VEGF和MMP-9水平均随着时间降低,且低于对照组,差异有统计学意义(P<0.05)。单抗联合组患者甲状腺功能减退发生率为18.18%,对照组为2.78%,差异有统计学意义(P<0.05);单抗联合组患者脱发和手足综合征发生率均为0,对照组分别为22.22%和27.78%,差异均有统计学意义(P<0.05)。所有患者中位随访时间为18个月,单抗联合组患者中位OS和中位PFS分别为16.9个月和4.8个月,对照组患者中位OS和中位PFS分别为10.5个月和3个月,两组比较差异有统计学意义(P<0.05)。结论 信迪利单抗联合贝伐珠单抗治疗可以较好地控制不可切除肝细胞肝癌患者病情发展,显著降低血清肿瘤相关因子水平,提高生存率,且安全性较好。

糖尿病性心肌病患者血清PDK4,DECR1和MMP1表达水平及临床价值研究

目的探讨血清丙酮酸脱氢酶激酶同工酶4(pyruvate dehydrogenase kinase isoenzyme 4,PDK4),2,4-二烯酰辅酶A还原酶1(2,4-dienoyl coenzyme A reductase 1,DECR1)及基质金属蛋白酶1(matrix metalloproteinase 1,MMP1)的联合检测在糖尿病性心肌病(diabetic cardiomyopathy,DCM)诊断、临床分级和病情预后中的应用价值。方法选取2021年10月~2023年10月陕西省人民医院收治的126例糖尿病性心肌病(DCM组)患者及120例单纯糖尿病非心肌病患者(对照组),采用酶联免疫吸附法(ELISA)测定血清中PDK4,DECR1及MMP1蛋白表达水平,评估这三个检测指标在DCM中的诊断、临床分级和病情预后中的应用价值。结果DCM组患者血清PDK4(131.38±10.20 pg/ml),DECR1(152.06±12.57 pg/ml)及MMP1(40.27±4.02μg/ml)蛋白表达水平与对照组(82.69±8.17 pg/ml,86.14±9.55 pg/ml,17.77±0.98μg/ml)相比均明显升高,差异具有统计学意义(t=36.24,47.63,12.29,均P<0.001)。DCM组患者血清PDK4,DECR1及MMP1蛋白表达水平与NYHA心功能分级相关,随等级升高其蛋白表达水平均明显升高,差异具有统计学意义(F=24.12,30.04,12.66,均P<0.001);DCM组中重度组患者与轻度组患者比较,血清PDK4(164.92±1.35pg/ml vs 122.48±8.78pg/ml),DECR1(192.17±9.11pg/ml vs124.36±10.83pg/ml)及MMP1(84.44±7.38μg/ml vs 39.41±3.05μg/ml)蛋白表达水平均显著增高,差异具有统计学意义(t=26.33,47.12,15.41,均P<0.001)。血清PDK4,DECR1及MMP1三项联合检测DCM准确度(χ^(2)=18.23,21.37,22.07)、特异度(χ^(2)=9.72,13.43,15.12)、灵敏度(χ^(2)=12.07,16.07,17.55)与单项检测对比均明显升高,差异具有统计学意义(均P<0.05),且ROC曲线分析结果显示联合检测的AUC高达0.955,明显高于单项检测(Z=16.67,17.09,20.44,均P<0.05)。结论血清PDK4,DECR1及MMP1与DCM诊断、临床分级及病情预后有一定关联,三者联合检测有助于DCM的鉴别诊断。